Voxelotor Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as GLOBAL BLOOD THERAPS. It is marketed under 1 brand name, including OXBRYTA. Available in 2 different strengths, such as 500MG, 300MG, and administered through 2 routes including TABLET;ORAL, TABLET, FOR SUSPENSION;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"88439","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"874c7362ae1f4b4db73e","publication_number":"US10017491B2","cleaned_patent_number":"10017491","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-12-28","publication_date":"2018-07-10","legal_status":"Granted"} US10017491B2 Formulation 10 Jul, 2018 Granted 28 Dec, 2032
{"application_id":"88375","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"bd5725b34515445c8bc4","publication_number":"US10034879B2","cleaned_patent_number":"10034879","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-12-28","publication_date":"2018-07-31","legal_status":"Granted"} US10034879B2 Molecular Formulation 31 Jul, 2018 Granted 28 Dec, 2032
{"application_id":"88430","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"bd5725b34515445c8bc4","publication_number":"US10806733B2","cleaned_patent_number":"10806733","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-12-28","publication_date":"2020-10-20","legal_status":"Granted"} US10806733B2 Molecular 20 Oct, 2020 Granted 28 Dec, 2032
{"application_id":"88429","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"bd5725b34515445c8bc4","publication_number":"US9018210B2","cleaned_patent_number":"9018210","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-11-25","publication_date":"2015-04-28","legal_status":"Granted"} US9018210B2 Molecular Formulation 28 Apr, 2015 Granted 25 Nov, 2033
{"application_id":"88324","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"8b7d560f86044a45a0c6","publication_number":"US9248199B2","cleaned_patent_number":"9248199","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-01-29","publication_date":"2016-02-02","legal_status":"Granted"} US9248199B2 02 Feb, 2016 Granted 29 Jan, 2034
{"application_id":"88325","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"f7b1d83bb59649f8996f","publication_number":"US9447071B2","cleaned_patent_number":"9447071","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-06","publication_date":"2016-09-20","legal_status":"Granted"} US9447071B2 Molecular Formulation 20 Sep, 2016 Granted 06 Feb, 2035
{"application_id":"88369","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"f7b1d83bb59649f8996f","publication_number":"US10722502B2","cleaned_patent_number":"10722502","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-06","publication_date":"2020-07-28","legal_status":"Granted"} US10722502B2 Formulation 28 Jul, 2020 Granted 06 Feb, 2035
{"application_id":"88371","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"4d7c2d2bb8e64579b2e9","publication_number":"US11452720B2","cleaned_patent_number":"11452720","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-06","publication_date":"2022-09-27","legal_status":"Granted"} US11452720B2 27 Sep, 2022 Granted 06 Feb, 2035
{"application_id":"123314","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"","publication_number":"US11944612B2","cleaned_patent_number":"11944612","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-12-02","publication_date":"2024-04-02","legal_status":"Granted"} US11944612B2 02 Apr, 2024 Granted 02 Dec, 2036
{"application_id":"88310","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"b8f3a48891714c039bde","publication_number":"US11020382B2","cleaned_patent_number":"11020382","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-12-02","publication_date":"2021-06-01","legal_status":"Granted"} US11020382B2 01 Jun, 2021 Granted 02 Dec, 2036
{"application_id":"97716","ingredient":"VOXELOTOR","trade_name":"OXBRYTA","family_id":"7e0077f47932497789cc","publication_number":"US10493035B2","cleaned_patent_number":"10493035","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-10-12","publication_date":"2019-12-03","legal_status":"Granted"} US10493035B2 Formulation 03 Dec, 2019 Granted 12 Oct, 2037

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Voxelotor

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.